Recursive partitioning for the prediction of cytochromes P450 2D6 and 1A2 inhibition: Importance of the quality of the dataset

Journal of Medicinal Chemistry

Volumn 49, Issue 21, 2006, Pages 6231-6240

  Burton, Julien ^a   Ijjaali, Ismail ^b   Barberan, Olivier ^b   Petitet, François ^b   Vercauteren, Daniel P ^a   Michel, André ^b  

^a UNIVERSITY OF NAMUR   (Belgium)

^b AUREUS PHARMA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUFURALOL; CLOMIPRAMINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; HYDROXYNEFAZODONE; IMIPRAMINE; NEFAZODONE;

ACCURACY; ARTICLE; COMPUTER PROGRAM; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; ENZYME INHIBITION; IC 50; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

ARTIFICIAL INTELLIGENCE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; DRUG DESIGN; ENZYME INHIBITORS; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SENSITIVITY AND SPECIFICITY; SOFTWARE;

EID: 33750118328     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060267u     Document Type: Article

References (43)

1. Kola, I.; Landis, J. Can the Pharmaceutical Industry Reduce Attrition Rates? Nature Rev. Drug Discovery 2004, 3, 711-715.
2. Nelson, D. R.; Koymans, L.; Kamataki, T.; Stegeman, J. J.; Feyereisen, R.; Waxman, D. J.; Waterman, M. R.; Gotoh, O.; Coon, M. J.; Estabrook, R. W.; Gunsalus, I. C.; Nebert, D. W. P450 Superfamily: Update on New Sequences, Gene Mapping, Accession Numbers and Nomenclature. Pharmacogenetics 1996, 6, 1-42.
3. Tredger, J. M.; Stoll, S. Cytochromes P450-Their Impact on Drug Treatment. Hosp. Pharmacist 2002, 9, 167-173.
4. Farrel, G. C. Drug-Induced Liver Disease, 1st ed.; Churchill Livingstone: New York, 1994.
5. Michalets, E. L. Clinically Significant Cytochrome P-450 Drug Interactions. Pharmacotherapy 1998, 18, 84-112.
6. Ekins, S.; Wrighton, S. A. Application of in Silica Approaches to Predicting Drug-Drug-Interactions. J. Pharm. Toxicicol. Methods 2001, 45, 65-69.
7. van de Waterbeemd, H.; Gifford, E. ADMET in Silico Modelling: Towards Prediction Paradise? Nature Rev. Drug Discovery 2003, 2, 192-204.
8. Susnow, R. G.; Dixon, S. L. Use of Robust Classification Techniques for the Prediction of Human Cytochrome P450 2D6 Inhibition. J. Chem. Inf. Comput. Sci. 2003, 43, 1308-1315.
9. Korolev, D.; Balakin, K. V.; Nikolsky, Y.; Kirillov, E.; Ivanenkov, Y. A.; Savchuk, N. P.; Ivashchenko, A. A.; Nikolskaya, T. Modeling of Human Cytochrome P450-Mediated Drug Metabolism Using Unsupervised Machine Learning Approach. J. Med. Chem. 2003, 46, 3631-3643.
10. Haji-Momenian, S.; Rieger, J. M.; Macdonald, T. L.; Brown, M. L. Comparative Molecular Field Analysis and QSAR on Substrates Binding to Cytochrome P450 2D6. Bioorg. Med. Chem. 2003, 11, 5545-5554.
11. Kemp, C. A.; Flanagan, J. U.; van Eldik, A. J.; Maréchal, J.-D.; Wolf, C. R.; Roberts, G. C. K.; Paine, M. J. I.; Sutcliffe, M. F. Validation of Model of Cytochrome P450 2D6: An in Silica Tool for Predicting Metabolism and Inhibition. J. Med. Chem. 2004, 47, 5340-5346.
12. Korhonen, L. E.; Rahnasto, M., Mähönen, N. J.; Wittekindt, C.; Poso, A.; Juvonen, R. O.; Raunio, H. Predictive Three-Dimensional Quantitative Structure-Activity Relationship of Cytochrome P450 1A2 Inhibitors. J. Med. Chem. 2005, 48, 3808-3815.
13. O'Brien, S. E.; de Groot, M. J. Greater Than the Sum of Its Parts: Combining Models for Useful ADMET Prediction. J. Med. Chem. 2005, 48, 1287-1291.
14. Chohan, K. K.; Paine, S. W.; Mistry, J.; Barton, P.; Davis, A. M. A Rapid Computational Filter for Cytochrome P450 1A2 Inhibition Potential of Compound Libraries. J. Med. Chem. 2005, 48, 5154-5161.
15. Yap, C. W.; Chen, Y. Z. Prediction of Cytochrome P450 3A4, 2D6, and 2C9 Inhibitors and Substrates by Using Support Vector Machines. J. Chem. Inf. Model. 2005, 45, 982-992.
16. Koziol, J. A.; Zhang, J. Y.; Casiano, C. A.; Peng, X. X.; Shi, F. D.; Feng, A. C.; Chan, E. K. L.; Tan, E. M. Recursive Partitioning as an Approach to Selection of Immune Markers for Tumor Diagnosis. Clin. Cancer Res. 2003, 9, 5120-5126.
17. Rusinko, A., III; Farmen, M. W.; Lambert, C. G.; Brown, P. L.; Young, S. S. Analysis of a Large Structure/Biological Activity Data Set Using Recursive Partitioning. J. Chem. Inf. Comput. Sci. 1999, 39, 1017-1026.
18. Jones-Hertzog, D. K.; Mukhopadhyay, P.; Keefer, C. E.; Young, S. S. Use of Recursive Partitioning in the Sequential Screening of G-Protein-Coupled Receptors. J. Pharm. Toxicol. 1999, 42, 207-215.
19. Godden, J. W.; Furr, J. R.; Bajorath, J. Recursive Median Partitioning for Virtual Screening of Large Databases. J. Chem. Inf. Comput. Sci. 2003, 43, 182-188.
20. van Rhee, A. M. Use of Recursion Forests in the Sequential Screening Process: Consensus Selection by Multiple Recursion Trees. J. Chem. Inf. Comput. Sci. 2003, 43, 941-948.
21. Baurin, N.; Mozziconacci, J. C.; Arnoult, E.; Chavatte, P.; Marot, C.; Morin-Allory, L. 2D QSAR Consensus Prediction for High-Throughput Virtual Screening. An Application to COX-2 Inhibition Modeling and Screening of the NCI Database. J. Chem. Inf. Comput. Sci. 2004, 44, 276-285.
22. Jchem, version 3.0.10, ChemAxon. 1037 Budapest, Hungary, www.chemaxon.com.
23. Ekins, S.; Bravi, G.; Binkley, S.; Gillespie J. S.; Ring, B. J.; Wikel, J. H.; Wrighton, S. A. Three and Four Dimensional-Quantitative Structure Activity Relationship (3D/4D-QSAR) Analyses of CYP2D6 inhibitors. Pharmacogenetics 1999, 9, 477-489.
24. de Groot, M. J.; Ackland, M. J.; Horne, V. A.; Alex, A. A.; Jones, B. C. A Novel Approach to Predicting P450 Mediated Drug Metabolism. CYP2D6 Catalyzed N-Dealkylation Reactions and Qualitative Metabolite Predictions Using a Combined Protein and Pharmacophore Model for CYP2D6. J. Med. Chem. 1999, 42, 4062-4070.
25. de Graaf, C.; Vermeulen, N. P. E.; Feenstra, K. A. Cytochrome P450 in Silico: An Integrative Modeling Approach. J. Med Chem. 2005, 48, 2725-2755.
26. Kalgutkar, A. S.; Zhou, S.; Fahmi, O. A.; Taylor, T. J. Influence of Lipophilicity on the Interactions of N-Alkyl-4-phenyl-1,2,3,6- tetrahydropyridines and Their Positively Charged N-Alkyl-4-phenylpyridinium Metabolites with Cytochrome P450 2D6. Drug Metab. Dispos. 2003, 31, 596-605.
27. Vaz, R. J.; Nayeem, A.; Santone, K.; Chandrasena, G.; Gavai, A. V. A 3D-QSAR Model for CYP2D6 Inhibition in the Aryloxypropanolamine Series. Bioorg. Med. Chem. Lett. 2005, 15, 3816-3820.
28. Ekins, S.; Berbaum, J.; Harrison, R. K. Generation and Validation of Rapid Computational Filters for CYP2D6 and CYP3A4. Drug Metab. Dispos. 2003, 31, 1077-1080.
29. Hall, L. H.; Kier, L. B. The Molecular Connectivity Chi Indices and Kappa Shape Indices in Structure-Property Modeling. Revi. Comput. Chem. 1991, 2, 367-422.
30. Hall, L. H.; Kier, L. B. The Nature of Structure-Activity Relationships and Their Relation to Molecular Connectivity. Eur. J. Med. Chem.-Chim. Ther. 1997, 4, 307-312.
31. Ekins, S.; de Groot, M. J.; Jones, J. P. Pharmacophore and Three-Dimensional Quantitative Structure Activity Relationship Methods for Modeling Cytochrome P450 Active Sites. Drug Metab. Dispos. 2001, 29, 936-944.
32. Specs, Delft, Holland, http://www.specs.net.
33. Baurin, N.; Baker, R.; Richardson, C.; Chen, I.; Foloppe, N.; Potter, A.; Jordan, A.; Roughley, S.; Parratt, M.; Greaney, P.; Morley, D.; Hubbard, R. E. Drug-like Annotation and Duplicate Analysis of a 23-Supplier Chemical Database Totaling 2.7 Million Compounds. J. Chem. Inf. Comput. Sci. 2004, 44, 643-651.
34. Aureus Pharma, Paris, 75010, France, http://www.aureus-pharma.com/.
35. MOE. Chemical Computing Group Inc., Montreal, H3A 2R7 Canada, http://www.chemcomp.com.
36. Labute, P. A Widely Applicable Set of Descriptors. J. Mol. Graph. Model. 2000, 18, 464-477.
37. Halgren, T. A Merck Molecular Force Field: I. Basis, Form, Scope, Parameterization, and Performance of MMFF94. J. Comput. Chem. 1996, 17, 490-519.
38. Maybridge Chemical Company Ltd., Cronwall. PL34 OHW England. http://www.maybridge.com.
39. Gasteiger, J.; Rudolph, C.; Sadowski, J. Automatic Generation of 3D Coordinates for Organic Molecules. Tetrahedron Comput. Methodol. 1990, 3, 537-547.
40. Sadowski, J.; Gasteiger, J. From Atoms and Bonds to Three-Dimensional Atomic Coordinates: Automatic Model Builders. Chem. Rev. 1993, 93, 2567-2581.
41. Sadowski, J.; Schwab, C. H.; Gasteiger, J. 3D Structure Generation and Conformational Searching. In Computational Medicinal Chemistry and Drug Discovery; P. Bultinck, H. De Winter, W. Langenaeker, J. P. Tollenaere, Ed.; Dekker Inc.: New York, 2003, pp 151-212.
42. Molecular Networks GmbH, 91052 Erlangen Germany http://www2.chemie.uni- erlangen.de/software/corina/index.html; http://www.mol-net.com/.
43. Jacobsson, M.; Lidén, P.; Stjernschantz, E.; Boström, H.; Norinder, U. Improving Structure-Based Virtual Screening by Multivariate Analysis of Scoring Data. J. Med. Chem. 2003, 46, 5781-5789.